MX390841B - Preparacion liquida parenteral que comprende compuesto de carbamato. - Google Patents
Preparacion liquida parenteral que comprende compuesto de carbamato.Info
- Publication number
- MX390841B MX390841B MX2019006939A MX2019006939A MX390841B MX 390841 B MX390841 B MX 390841B MX 2019006939 A MX2019006939 A MX 2019006939A MX 2019006939 A MX2019006939 A MX 2019006939A MX 390841 B MX390841 B MX 390841B
- Authority
- MX
- Mexico
- Prior art keywords
- carbamate compound
- parenteral preparation
- liquid parenteral
- liquid
- solvate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170389 | 2016-12-14 | ||
| PCT/KR2017/014727 WO2018111000A1 (ko) | 2016-12-14 | 2017-12-14 | 카바메이트 화합물을 포함하는 비경구용 액상 제제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019006939A MX2019006939A (es) | 2019-09-13 |
| MX390841B true MX390841B (es) | 2025-03-21 |
Family
ID=62559693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006939A MX390841B (es) | 2016-12-14 | 2017-12-14 | Preparacion liquida parenteral que comprende compuesto de carbamato. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12070447B2 (enExample) |
| EP (1) | EP3556349B1 (enExample) |
| JP (1) | JP7110196B2 (enExample) |
| KR (1) | KR102605030B1 (enExample) |
| CN (2) | CN118766839A (enExample) |
| AU (1) | AU2017374450B2 (enExample) |
| CL (1) | CL2019001617A1 (enExample) |
| DK (1) | DK3556349T3 (enExample) |
| ES (1) | ES2901427T3 (enExample) |
| IL (1) | IL267192B2 (enExample) |
| MX (1) | MX390841B (enExample) |
| MY (1) | MY200159A (enExample) |
| PL (1) | PL3556349T3 (enExample) |
| PT (1) | PT3556349T (enExample) |
| RU (1) | RU2761041C2 (enExample) |
| WO (1) | WO2018111000A1 (enExample) |
| ZA (1) | ZA201903748B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111432812A (zh) | 2017-11-14 | 2020-07-17 | 爱思开生物制药株式会社 | 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途 |
| IL281559B2 (en) * | 2018-09-21 | 2025-06-01 | Sk Biopharmaceuticals Co Ltd | (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| CN113242735A (zh) * | 2018-09-21 | 2021-08-10 | 爱思开生物制药株式会社 | 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| WO2007041524A2 (en) * | 2005-09-30 | 2007-04-12 | Ovation Pharmaceuticals, Inc. | Novel parenteral carbamazepine formulation |
| US20100204178A1 (en) * | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| RU2462261C2 (ru) * | 2006-06-29 | 2012-09-27 | Ариджен, Фармасьютикалз, Инк. | Пригодный для инъекции состав антибиотика и раствор для его внутривенного введения |
| CN101686681B (zh) * | 2007-04-27 | 2015-04-01 | 锡德克斯药物公司 | 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法 |
| AU2009348523B2 (en) | 2009-06-22 | 2015-02-26 | Sk Biopharmaceuticals Co., Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
-
2017
- 2017-12-14 MY MYPI2019003346A patent/MY200159A/en unknown
- 2017-12-14 PT PT178803359T patent/PT3556349T/pt unknown
- 2017-12-14 CN CN202410768574.7A patent/CN118766839A/zh active Pending
- 2017-12-14 PL PL17880335T patent/PL3556349T3/pl unknown
- 2017-12-14 CN CN201780077651.2A patent/CN110267647A/zh active Pending
- 2017-12-14 RU RU2019121911A patent/RU2761041C2/ru active
- 2017-12-14 ES ES17880335T patent/ES2901427T3/es active Active
- 2017-12-14 EP EP17880335.9A patent/EP3556349B1/en active Active
- 2017-12-14 KR KR1020197018404A patent/KR102605030B1/ko active Active
- 2017-12-14 AU AU2017374450A patent/AU2017374450B2/en active Active
- 2017-12-14 US US16/468,756 patent/US12070447B2/en active Active
- 2017-12-14 WO PCT/KR2017/014727 patent/WO2018111000A1/ko not_active Ceased
- 2017-12-14 MX MX2019006939A patent/MX390841B/es unknown
- 2017-12-14 DK DK17880335.9T patent/DK3556349T3/da active
- 2017-12-14 JP JP2019531627A patent/JP7110196B2/ja active Active
-
2019
- 2019-06-10 IL IL267192A patent/IL267192B2/en unknown
- 2019-06-11 ZA ZA2019/03748A patent/ZA201903748B/en unknown
- 2019-06-12 CL CL2019001617A patent/CL2019001617A1/es unknown
-
2024
- 2024-07-22 US US18/779,456 patent/US20240374568A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2901427T3 (es) | 2022-03-22 |
| EP3556349A1 (en) | 2019-10-23 |
| IL267192A (enExample) | 2019-07-31 |
| DK3556349T3 (da) | 2022-01-03 |
| RU2019121911A (ru) | 2021-01-15 |
| KR20190087568A (ko) | 2019-07-24 |
| CN110267647A (zh) | 2019-09-20 |
| RU2761041C2 (ru) | 2021-12-02 |
| IL267192B2 (en) | 2023-05-01 |
| ZA201903748B (en) | 2020-12-23 |
| US20190314336A1 (en) | 2019-10-17 |
| PL3556349T3 (pl) | 2022-04-11 |
| BR112019011914A2 (pt) | 2019-11-05 |
| CL2019001617A1 (es) | 2019-08-23 |
| MX2019006939A (es) | 2019-09-13 |
| PT3556349T (pt) | 2021-12-28 |
| US20240374568A1 (en) | 2024-11-14 |
| EP3556349A4 (en) | 2020-07-01 |
| EP3556349B1 (en) | 2021-11-24 |
| JP7110196B2 (ja) | 2022-08-01 |
| RU2019121911A3 (enExample) | 2021-03-05 |
| AU2017374450B2 (en) | 2023-05-11 |
| CA3046458A1 (en) | 2018-06-21 |
| KR102605030B1 (ko) | 2023-11-23 |
| US12070447B2 (en) | 2024-08-27 |
| CN118766839A (zh) | 2024-10-15 |
| AU2017374450A1 (en) | 2019-07-04 |
| WO2018111000A1 (ko) | 2018-06-21 |
| MY200159A (en) | 2023-12-09 |
| IL267192B1 (en) | 2023-01-01 |
| JP2020502108A (ja) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| CO2020007162A2 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| PH12016501813A1 (en) | 1,3-benzodioxole derivative | |
| MX2017002028A (es) | Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7). | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| MX2019009185A (es) | Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende. | |
| AR090456A1 (es) | Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| MX362383B (es) | Moduladores de acido oxabiciclo[2.2.2] gpr120. | |
| MY192425A (en) | Polymorphs | |
| EA201691670A1 (ru) | Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2 | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| CO2018001383A2 (es) | Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp” | |
| ECSP16096831A (es) | Derivados de naftiridinadiona | |
| NZ721780A (en) | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections | |
| DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| AR090073A1 (es) | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| CL2019001617A1 (es) | Preparación líquida parenteral que comprende compuesto de carbamato. | |
| CL2019002025A1 (es) | Derivados de pirrolotriazina como inhibidor de cinasas. | |
| MX380172B (es) | Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. | |
| MX2021009261A (es) | Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1. | |
| EA201791397A1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| MX2018000677A (es) | Derivado de urea y uso del mismo. |